At Akron Bio, we’re a people-focused company. Our customers, our staff, the patients using our products—these are the core of everything we do.
Expect more out of your pDNA service provider. At Akron Bio, we manufacture a robust product with high yields and unmatched purity.
Our pharma quality cGMP Recombinant Proteins power today’s leading clinical and commercial cell therapy companies.
Akron’s virus-inactivated product line starts with Octaplas®—a pharmaceutically licensed, virally inactivated plasma—which makes for greater batch-to-batch consistency and a unique safety profile.
With end-to-end custom process development and manufacturing services, we take you from where you are to where you need to be.
Akron’s high-quality cGMP Recombinant Proteins offer the consistency, safety, and efficacy that empower today’s leading clinical and commercial cell therapy companies.
Akron’s proven blood products deliver safety and performance backed by robust and redundant supply. Because you can’t afford to compromise.
Capitalizing on our established platform for manufacturing cGMP-compliant, clinical-grade ancillary products, Akron is well-positioned to provide custom development and manufacturing to accelerate the commercialization of advanced therapies.
At Akron, we manufacture high-quality compliant cGMP plasmid DNA for pre-clinical, clinical, and commercial gene therapy and vaccine companies where material needs are 1+ grams.
Miami Beach, FL
We are thrilled to be a platinum sponsor & exhibitor at Advanced Therapies Week. We hope to see you there!
Akron Bio's Business Development Director Sara Padrell will be speaking at the Next Gen CAR-TCR Summit regarding Akron's new line of Closed System Solutions™. We hope to see you there!
Apr 07, 2021
Akron Biotech appoints new Scientific Advisory Board, further expanding its cell and gene therapy industry expertise
Feb 24, 2021
De-risking the Manufacturing of Cell Therapies through Virus-Inactivated Products, Upcoming Webinar Hosted by Xtalks
Jan 20, 2021
Akron Biotech Signs Exclusive Global Agreement with Octapharma to Produce Virally Inactivated Human AB Serum Derived from Octaplas® for the Cell Therapy Market